Search

Pixavir marboxil

Pixavir marboxil is a small molecule drug. The usage of the INN stem '-xavir' in the name indicates that Pixavir marboxil is a influenza CAP-dependent endonuclease inhibitor. … Pixavir marboxil has a monoisotopic molecular weight of 540.12 Da.

Lotrafiban

Lotrafiban is a small molecule drug. The usage of the INN stem '-fiban' in the name indicates that Lotrafiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist). … Lotrafiban has a monoisotopic molecular weight of 428.24 Da.

Tegoprazan

[A234215, A234220] This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fast onset of action and the ability to control gastric pH for a prolonged period of time. … Tegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases.

Davunetide

Davunetide is derived from a naturally occurring neuroprotective brain protein known as activity dependent neuroprotective protein. … Davunetide has been used in trials studying the treatment of Progressive Nonfluent Aphasia, Progressive Supranuclear Palsy, Predicted Tauopathies, Including, Corticobasal Degeneration Syndrome, and Frontotemporal

Sonpiretigene isteparvovec

Sonpiretigene isteparvovec is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy. … [L46676] Sonpiretigene isteparvovec consists of a fusion Adeno-associated virus (AAV) vector with three plasmids encoding opsins with spectrally-separated activation peaks.[L46681]

Antithymocyte immunoglobulin (rabbit)

Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. … Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells.

UB-612

This vaccine was designed to induce a broad immune response. It was able to reduce viral load and prevent COVID-19 infection in a mouse challenge model and in rhesus macaques[L30653, L30658]. … In addition, the vaccine contains a proprietary peptide UBITh®1a for enhanced immunogenicity, five identified peptides with Th or CTL epitopes to improve peptide solubility, and aluminum phosphate adjuvant

Briakinumab

As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. … Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases.

XAV-19

Xenothera has partnered with LFB, a pharmaceutical company, to develop XAV-19, and with Nantes University Hospital to test the treatment in patients[L16553,L16558]. … XAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses[L16553,L16558]. The therapy concept is based on [COVID-19 convalescent plasma].

Sapacitabine